Celiac Disease Pipeline Analysis 2024: Clinical Trials, FDA Approvals, Emerging Therapies, ROA, MOA and Treatment Outlook by DelveInsight | Amgen, AMYRA Biotec, Equillium Bio, Chugai Pharmaceutical

As per DelveInsight's assessment, globally, Celiac Disease pipeline constitutes 25+ key companies continuously working towards developing 25+ Celiac Disease treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
(New York, United States) "Celiac Disease Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Celiac Disease Market.

The Celiac Disease Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Request for Sample Report @ Celiac Disease Pipeline Outlook [https://www.delveinsight.com/report-store/celiac-disease-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Some of the key takeaways from the Celiac Disease Pipeline Report:

* Celiac Disease Companies across the globe are diligently working toward developing novel Celiac Disease treatment therapies with a considerable amount of success over the years.
* Celiac Disease companies working in the treatment market are 9Metres Biopharma, Amgen, Allero Therapeutics, Takeda, Calypso Biotech, Anokion, Zedira GmbH, Millennium Pharmaceuticals, ImmunogenX, GlaxoSmithKline, ImmusanT, ActoBio Therapeutics, Amyra biotech, and others, are developing therapies for the Celiac Disease treatment

* Emerging Celiac Disease therapies in the different phases of clinical trials are- AMY02, EQ102, DONQ52, CALY-002, Latiglutenase, Ordesekimab, and others are expected to have a significant impact on the Celiac Disease market in the coming years.
* On March 2024, Takeda announced results of a Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of TAK-062 for the Treatment of Active Celiac Disease in Subjects Attempting a Gluten-Free Diet
* On March 2024, Kanyos Bio, Inc., a wholly-owned subsidiary of Anokion SA announced results of a Phase 2a Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of KAN-101 In Participants With Celiac Disease.
* On December 2023, Topas Therapeutics GmbH announced results of a Double-blind, Randomized, Placebo-controlled, Phase 2a Study to Evaluate the Safety, Tolerability, and Pharmacodynamic (PD) Effects of Two Infusions of Escalating Doses of TPM502 in Adults Diagnosed With Celiac Disease.
* On November 2023, Chugai Pharmaceutical announced results of a Phase I, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate The Safety, Tolerability, Pharmacokinetics, and Biomarkers of DONQ52 in Celiac Disease Patients (LILY Study).
* On September 2023, Regeneron Pharmaceuticals announced results of a study based on T Cell Receptor (TCR) Sequencing and Transcriptional Profiling in Adult Celiac Disease Patients Undergoing Gluten Challenge.

Celiac Disease Overview

Celiac disease is an autoimmune disorder triggered by the ingestion of gluten-a protein found in wheat, barley, and rye-in genetically predisposed individuals. When someone with celiac disease consumes gluten, their immune system responds by damaging the lining of the small intestine. This damage impairs the absorption of nutrients from food, leading to various symptoms and potential long-term complications.

Symptoms of celiac disease can vary widely and may include gastrointestinal issues like diarrhea, abdominal pain, bloating, and constipation, as well as non-gastrointestinal symptoms such as fatigue, joint pain, skin rashes, and neurological problems.

Diagnosis typically involves blood tests to check for specific antibodies associated with celiac disease, followed by confirmation through a biopsy of the small intestine to assess for characteristic damage to the intestinal lining.

The primary treatment for celiac disease is strict adherence to a gluten-free diet, which involves avoiding all foods containing wheat, barley, and rye. This typically leads to symptom resolution, intestinal healing, and prevention of complications. Additionally, individuals with celiac disease may benefit from nutritional supplementation and regular monitoring by healthcare professionals to ensure optimal management of the condition and prevent potential deficiencies or complications.

Get a Free Sample PDF Report to know more about Celiac Disease Pipeline Therapeutic Assessment- https://www.delveinsight.com/sample-request/celiac-disease-pipeline-insight [https://www.delveinsight.com/sample-request/celiac-disease-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Emerging Celiac Disease Drugs Under Different Phases of Clinical Development Include:

* AMY02 : AMYRA Biotech AG
* EQ102 : Equillium Bio.
* DONQ52 : Chugai Pharmaceutical Co., Ltd.
* CALY-002 : Calypso Biotech
* Latiglutenase : ImmunogenX, Inc.
* Ordesekimab : Amgen Inc.

Celiac Disease Route of Administration

Celiac Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

* Intra-articular
* Intraocular
* Intrathecal
* Intravenous
* Ophthalmic
* Oral
* Parenteral
* Subcutaneous
* Topical
* Transdermal
* Molecule Type

Celiac Disease Molecule Type

Celiac Disease Products have been categorized under various Molecule types, such as

* Oligonucleotide
* Peptide
* Small molecule

Celiac Disease Pipeline Therapeutics Assessment

* Celiac Disease Assessment by Product Type
* Celiac Disease By Stage and Product Type
* Celiac Disease Assessment by Route of Administration
* Celiac Disease By Stage and Route of Administration
* Celiac Disease Assessment by Molecule Type
* Celiac Disease by Stage and Molecule Type

DelveInsight's Celiac Disease Report covers around 25+ products under different phases of clinical development like

* Late-stage products (Phase III)
* Mid-stage products (Phase II)
* Early-stage product (Phase I)
* Pre-clinical and Discovery stage candidates
* Discontinued & Inactive candidates
* Route of Administration

Further Celiac Disease product details are provided in the report. Download the Celiac Disease pipeline report to learn more about the emerging Celiac Disease therapies- https://www.delveinsight.com/sample-request/celiac-disease-pipeline-insight [https://www.delveinsight.com/sample-request/celiac-disease-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Some of the key companies in the Celiac Disease Therapeutics Market include:

Key companies developing therapies for Celiac Disease are - 9 Metres Biopharma, Amgen, Allero Therapeutics, Takeda, Calypso Biotech, Anokion, Zedira GmbH, Millennium Pharmaceuticals, ImmunogenX, GlaxoSmithKline, ImmusanT, ActoBio Therapeutics, Amyra biotech, and others.

Celiac Disease Pipeline Analysis:

The Celiac Disease pipeline report provides insights into

* The report provides detailed insights about companies that are developing therapies for the treatment of Celiac Disease with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Celiac Disease Treatment.
* Celiac Disease key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Celiac Disease Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Celiac Disease market.

The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Celiac Disease drugs and therapies - https://www.delveinsight.com/sample-request/celiac-disease-pipeline-insight [https://www.delveinsight.com/sample-request/celiac-disease-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Celiac Disease Pipeline Market Drivers

Increasing prevalence of Celiac Disease, increasing R&D activities, no Approved Therapy are some of the important factors that are fueling the Celiac Disease Market.

Celiac Disease Pipeline Market Barriers

However, limited patient awareness about the disease, poor Patient Compliance and other factors are creating obstacles in the Celiac Disease Market growth.

Scope of Celiac Disease Pipeline Drug Insight

* Coverage: Global
* Key Celiac Disease Companies: 9Metres Biopharma, Amgen, Allero Therapeutics, Takeda, Calypso Biotech, Anokion, Zedira GmbH, Millennium Pharmaceuticals, ImmunogenX, GlaxoSmithKline, ImmusanT, ActoBio Therapeutics, Amyra biotech, and others
* Key Celiac Disease Therapies: AMY02, EQ102, DONQ52, CALY-002, Latiglutenase, Ordesekimab, and others
* Celiac Disease Therapeutic Assessment: Celiac Disease current marketed and Celiac Disease emerging therapies
* Celiac Disease Market Dynamics: Celiac Disease market drivers and Celiac Disease market barriers

Request for Sample PDF Report for Celiac Disease Pipeline Assessment and clinical trials - https://www.delveinsight.com/sample-request/celiac-disease-pipeline-insight [https://www.delveinsight.com/sample-request/celiac-disease-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Table of Contents

1. Celiac Disease Report Introduction

2. Celiac Disease Executive Summary

3. Celiac Disease Overview

4. Celiac Disease- Analytical Perspective In-depth Commercial Assessment

5. Celiac Disease Pipeline Therapeutics

6. Celiac Disease Late Stage Products (Phase II/III)

7. Celiac Disease Mid Stage Products (Phase II)

8. Celiac Disease Early Stage Products (Phase I)

9. Celiac Disease Preclinical Stage Products

10. Celiac Disease Therapeutics Assessment

11. Celiac Disease Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Celiac Disease Key Companies

14. Celiac Disease Key Products

15. Celiac Disease Unmet Needs

16 . Celiac Disease Market Drivers and Barriers

17. Celiac Disease Future Perspectives and Conclusion

18. Celiac Disease Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Ankit Nigam
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=celiac-disease-pipeline-analysis-2024-clinical-trials-fda-approvals-emerging-therapies-roa-moa-and-treatment-outlook-by-delveinsight-amgen-amyra-biotec-equillium-bio-chugai-pharmaceutical]
Phone: +14699457679
Address:304 S. Jones Blvd #2432, Las Vegas NV 89107
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services



This release was published on openPR.